Literature DB >> 30104891

High prevalence of hypervirulent Klebsiella pneumoniae infection in the genetic background of elderly patients in two teaching hospitals in China.

Chao Liu1, Jiaojiao Shi2, Jun Guo3,4.   

Abstract

PURPOSE: Aerobactin is a critical factor for hypervirulent Klebsiella pneumoniae (hvKp) in genetic backgrounds, but data based on the genotype for the elderly is limited.
MATERIALS AND METHODS: A retrospective study was conducted on elderly patients from June 2008 to July 2017 in 2 teaching hospitals. The clinical and microbiological data, including antimicrobial susceptibility testing, string test, extended-spectrum β-lactamase (ESBL) production, virulence gene, and multilocus sequence typing, of the hvKp group defined as aerobactin positive were compared with those of classic K. pneumoniae isolates.
RESULTS: A total of 45.7% of 202 K. pneumoniae isolates were hvKp.ST23, which were predominant in 2 hospitals, but they were not highly associated with hvKp in different hospitals. Hypermucoviscosity, K1, K2, magA, and rmpA/A2 genes were highly related to hvKp (P=0.000). With regard to the host, invasive infections (P=0.000), liver abscess (P=0.000), abdominal infection (P=0.000), pneumonia (P=0.037), and septic shock (P=0.045) were significantly higher in the elderly with hvKp. In the hvKp group, patients with better nutritional status were associated with a more severe sequential organ failure assessment score and a more serious inflammation reaction. Patients with diabetes (odds ratio [OR]=2.566) are more likely to be infected with hvKp. Previous hvKp is associated with hypermucoviscosity (OR=15.249) are often paralleled with hvKp. Importantly, 26% of hvKp isolates produced ESBLs, and most of them showed a carbapenems-resistant (CR) phenotype. Multivariate analysis implied that patients with a history of surgery within the last 1 month (OR=15.999) is an independent risk factor for CR-hvKp infection.
CONCLUSION: The prevalence of hvKP is high in the elderly. ESBL-hvKp, especially CR-hvKp, is emerging, which is a sign that clinical awareness and infection monitoring needs to improve.

Entities:  

Keywords:  CR-hvKp; ESBL-hvKp; Klebsiella pneumoniae; aerobactin; hypervirulent; risk factor

Year:  2018        PMID: 30104891      PMCID: PMC6074765          DOI: 10.2147/IDR.S161075

Source DB:  PubMed          Journal:  Infect Drug Resist        ISSN: 1178-6973            Impact factor:   4.003


Introduction

Klebsiella pneumoniae is a Gram-negative bacterium, causing various fatal infections. There are 2 pathotypes: hypervirulent (hvKp) and classical (cKp), which are detrimental to our health. Initially, a string test with a length >5 mm was defined as hypermucoviscosity, which is a traditional unique hvKp trait, triggering aggressive invasive infection, such as bloodstream infection and pyogenic liver abscesses (PLAs) for immunocompetent ambulatory younger individuals with non-underlying diseases.1–4 However, many studies do not agree with the definition of hvKp defined by hypermucoviscosity phenotype.5,6 The reason is that few hypermucoviscous K. pneumoniae (hmvKp) strains are associated with high virulence with in vitro and in vivo assays.5,6 Thus, using hvKp by hypermucoviscosity phenotype as the sole indicator of hvKp is not appropriate.7,8 Until recently, aerobactin, the dominant siderophore, was regarded as a critical virulence factor for hvKp genetic background.1,8,9 A multicenter study, focusing on middle-aged patients, first demonstrated the clinical and molecular characteristic of hvKp (defined as aerobactin positive) infection.8 But data are limited on the elderly who may have various underlying diseases, nutrition status, and atypical manifestations, along with being infected with genotype hvKp. Many previous studies have illustrated that hvKp is sensitive to most antibiotics, which is not frequently present in infection with cKp strains. But emerging multidrug resistance (MDR) hvKp, especially resistant to colistin and carbapenems, has been reported in China.10–12 However, there are not enough adapted data on the elderly and the characteristics of antimicrobial-resistant hvKp infection. Thus, for further investigation of the prevalence and antibiotic resistance of hvKp, we conducted a retrospective study in 2 teaching hospitals based on the genotype of hvKp, which was defined as aerobactin positive.

Materials and methods

Patients

A retrospective study was conducted on 202 K. pneumoniae culture-positive patients diagnosed at Beijing Tsinghua Changgung Hospital and Chinese PLA General Hospital from June 2008 to July 2017. The definition of elderly was if the patient was ≥65 years. Duplicate isolates from the same patient were excluded. The clinical characteristics, including underlying disease, infection type, nutritional status, mortality in 30 days, and sequential organ failure assessment (SOFA), were collected. To recognize the host responsibility and nutritional status between the 2 pathotypes, white blood cell count (WBC) and neutrophil percentage (NEU%) were used as primary and rough inflammatory factors. To evaluate the nutrition status, we used total protein (TP) and albumin (ALB) as markers. The study was approved by the Chinese PLA General Hospital Ethics Committee, and the Guidelines for Human Experimentation (China) were followed through the whole study. Informed consent was not needed due to the retrospective nature of the study; additionally, the patient data accessed in this research was anonymous. Therefore, the Chinese PLA General Hospital Ethics Committee waived the need for consent.

K. pneumoniae strains

All isolates were stored at −80°C and previously identified by the API 20 NE system and the Vitek II system. Additionally, species identification was further confirmed by 16S rRNA gene sequencing. HvKp was defined as aerobactin positive. Hypermucoviscous phenotype was confirmed by string test as described previously.13

Antimicrobial susceptibility testing and phenotypic detection of ESBLs

Antimicrobial susceptibility testing was conducted and the results were interpreted by 2017 Clinical and Laboratory Standards Institute (CLSI) guidelines. The antibiotics include amikacin, gentamicin, tobramycin, ampicillin/sulbactam, aztreonam, cefazolin, cefepime, ceftriaxone, ceftazidime, ciprofloxacin, levofloxacin, piperacillin/tazobactam, and trimethoprim/sulfamethoxazole. ESBL was confirmed by agar dilution test using ceftazidime and cefotaxime combined with clavulanate according to the CLSI guidelines.8 MDR strains were defined as resistant to ≥3 different antimicrobial categories.14 Isolates that are resistant to both imipenem and meropenem are defined as carbapenems-resistant (CR) isolates.

Detection of virulence gene

Genomic DNA of all K. pneumoniae isolates was extracted. Virulence-associated genes (rmpA, rmpA2, magA, and aerobactin) and capsular serotype-specific (cps) genes (K1, K2, K5, K20, K54, and K57) were amplified by polymerase chain reaction (PCR).8,15–17 The primers are listed in Table S1.

Multilocus sequence typing (MLST) for K. pneumoniae

Seven housekeeping genes (gapA, mdh, phoE, tonB, infB, pgi, and rpoB) were amplified by PCR following the protocol (http://bigsdb.pasteur.fr/klebsiella/klebsiella.html) (Table S1). Allelic profiling and sequence types (STs) determination were also confirmed on the aforementioned website. Moreover, to further analyze the relationship among different STs, phylogenetic analysis of spliced 7 housekeeping genes for frequency >1 isolates and strains contributing to invasive infection and mortality was performed by the neighbor-joining method (MEGA 7.0).

Statistical analysis

SPSS software (version 20.0; IBM Corporation, Armonk, NY, USA) was performed for data analysis. Measurement data were assessed as mean ± SD. The count data was analyzed as percentages. Continuous variables were analyzed by Student’s t-tests and the Wilcoxon rank-sum tests. Categorical variables were analyzed by χ2 or Fisher’s exact test. Univariate logistic regression analyses were performed for risk factor. To further analyze independent risk factors, a multivariable logistic regression analysis was conducted. All variables with P values of <0.05 were included in the multivariate model. All tests were 2-tailed. P-value <0.05 was considered significant.

Results

Patient characteristics

A total of 202 K. pneumoniae culture-positive patients were diagnosed at the 2 hospitals from June 2008 to July 2017. A total of 96 (47.5%) isolates were hvKp and 121 (59.9%) were hmvKp. All the PLA patients (10 cases) were infected with hvKp. The main infection type distribution in hospital was pneumonia (146, 72.3%), while other infection types included urinary infection (42, 20.8%), invasive infection (37, 18.3%), and abdominal infection (26, 12.9%). Moreover, almost half of the patients (98, 48.5%) presented with sepsis, and 24 (11.9%) were diagnosed as septic shock. A total of 181 (89.6%) were males and 21 (10.4%) were females; the mean age was 84.43±7.84 years.

Clinical features: hvKp vs. cKp

Clinical features are shown in Table 1. The mean age of the hvKp group was younger than the cKp group (83.24±7.35 vs. 85.5±8.14 years, P=0.039). Diabetes (72.9% vs. 48.1%; P=0.000) and digestive diseases (22.9% vs. 13.5%; P=0.046) were highly associated with the hvKp group as their underlying diseases. Compared with the cKp group, a significantly higher number of patients with the hvKp presented with invasive infections (30.2% vs. 7.5%; P=0.000), liver abscess (10.4% vs. 0%; P=0.000), other abscess (26.0% vs. 2.8%; P=0.035), septic shock (16.7% vs. 7.5%; P=0.045), pneumonia (79.2% vs. 66.0%; P=0.037), and abdominal infection (21.9% vs. 4.7%; P=0.000). However, the incidence rates of urinary infection (13.5% vs. 27.4%, P=0.016) and stomach tube indwelling (60.4% vs. 77.4%, P=0.009) were comparably lower in the hvKp group.
Table 1

Clinical and microbiological features of hvKp

CharacteristichvKp (N=96)cKp (N=106)P-value
K serotype
K133 (34.4%)2 (1.9%)0.000
K220 (20.8%)2 (1.9%)0.000
K53 (3.1%)0 (0%)0.106
K206 (6.3%)4 (3.8%)0.627
K544 (3.8%)3 (2.8%)0.894
K5710 (10.4%)6 (6.3%)0.211
rmpA76 (79.2%)12 (11.3%)0.000
rmpA268 (70.8%)15 (14.2%)0.000
magA77 (80.2%)50 (47.2%)0.000
Hypermucoviscosity86 (89.6%)35 (33.0%)0.000
Basic demographics
Age83.24±7.3585.5±8.140.039
Male93 (96.9%)88 (83.0%)0.361
Underlying diseases
Pulmonary disease86 (89.6%)85 (80.2%)0.064
Diabetes70 (72.9%)51 (48.1%)0.000
Cardiovascular disease45 (46.9%)60 (56.6%)0.167
Cerebrovascular disease15 (15.6%)27 (25.5%)0.085
Cancer28 (29.2%)27 (25.5%)0.556
Surgery within 1 month14 (14.6%)11 (10.4%)0.365
Digestive disease22 (22.9%)13 (13.5%)0.046
Catheter
Central intravenous catheter65 (67.7%)66 (62.3%)0. 418
Urinary catheter73 (76.0%)87 (82.1%)0.291
Tracheal catheter34 (35.4%)39 (36.8%)0.839
Stomach tube58 (60.4%)82 (77.4%)0.009
Infection type
Pneumonia76 (79.2%)70 (66.0%)0.037
Urinary infection13 (13.5%)29 (27.4%)0.016
Invasive infection29 (30.2%)8 (7.5%)0.000
 Bacteremia8 (8.3%)4 (3.8%)0.171
 Liver abscess10 (10.4%)0 (0%)0.000
 Other abscess25 (26.0%)3 (2.8%)0.000
Abdominal infection21 (21.9%)5 (4.7%)0.000
Sepsis48 (50.0%)50 (47.2%)0.688
Septic shock16 (16.7%)8 (7.5%)0.045
Host responsibility
WBC (109/L)12.74±3.9410.59±3.480.000
NEU%78.70±8.0275.6±8.500.003
Nutrition status
TP64.74±5.4262.83±6.320.023
ALB34.98±3.4033.78±3.730.019
SOFA score6.79±2.884.91±2.610.000
Infection occurred in ICU19 (19.8%)16 (15.1%)0.378
Mortality in 30 days16 (16.7%)23 (21.7%)0.366

Notes: Data presented as mean ± standard deviation, unless otherwise stated. Bold values indicate P<0.05.

Abbreviations: ALB, albumin; cKp, classic Klebsiella pneumoniae; ESBLs, extended-spectrum β-lactamases; hvKp, hypervirulent Klebsiella pneumoniae; ICU, intensive care unit; NEU%, neutrophil percentage; SOFA, sequential organ failure assessment; TP, total protein; WBC, white blood cell count.

WBC (12.74±3.94 109/L vs. 10.59±3.48 109/L, P=0.000) and NEU% (78.70±8.02 vs. 75.60±8.50, P=0.003) of patients with hvKp, represented as host responsibility, were significantly higher than cKp group. However, patients infected with hvKp were more likely to have a poorer nutritional status in TP (64.74±5.42 vs. 62.83±6.32, P=0.023) and ALB (34.98±3.40 vs. 33.78±3.73, P=0.019). Moreover, although the mortality in 30 days (16.7% vs. 21.7%, P=0.366) was not significantly different, SOFA score in patients with hvKp was notably higher (6.79±2.88 vs. 4.93±2.59, P=0.000; Table 1).

Genetic and phenotype characteristics: hvKp vs. cKp

Previous studies confirmed that virulence-associated genes (rmpA, rmpA2, and magA) and cps genes (K1, K2, K5, K20, K54, and K57) are clustered in the hvKp group.18–20 A significant difference was that K1, K2, rmpA, rmpA2, and magA were highly clustered in hvKp (P=0.000, respectively), and K5, K20, K54, and K57 were not associated with hvKp (P=0.106, 0.627, 0.894, and 0.211, respectively). There was no strain in the cKp group with K5 (Table 1). It was strongly noted that hypermucoviscosity was highly associated with hvKp (P=0.000).

Antimicrobial resistance and prevalence of ESBL-producing K. pneumoniae isolates

Most of the hvKp isolates were sensitive to most of the antibiotics, with the exception of ampicillin, imipenem, and meropenem (Table 2). All Kp strains were resistant to ampicillin. In the hvKp group, 24 strains (25.0%) were MDR. A total of 25 hvKp isolates were identified as ESBL-producing K. pneumoniae isolates, which were more common in the cKp group (53.8% vs. 26.0%, P=0.001). One CR-hvKp isolate existed in one of these 2 teaching hospitals. In another referral center, 10 CR-hvKp strains were detected. The detailed information for the 11 CR-hvKp strains is shown in Table S2.
Table 2

Antibiotic resistance: hvKp vs. cKp

Antibiotic agenthvKp (N=96)cKp (N=106)P-value
ESBLs25 (16.3%)57 (40.0%)0.000
Amikacin10 (2.5%)22 (11.6%)0.044
Gentamicin16 (8.8%)41 (29.5%)0.001
Ampicillin/sulbactam28 (20.0%)60 (44.2%)0.000
Aztreonam18 (8.8%)41 (23.2%)0.002
Cefazolin28 (18.8%)59 (44.2%)0.000
Cefotetan14 (14.6%)31 (29.2%)0.012
Cefepime15 (5.0%)34 (14.7%)0.006
Ceftriaxone25 (16.3%)51 (34.7%)0.001
Ceftazidime17 (7.5%)43 (25.3%)0.000
Ciprofloxacin18 (10.0%)43 (25.3%)0.001
Levofloxacin14 (6.3%)40 (22.1%)0.000
Trimethoprim/sulfamethoxazole15 (8.8%)44 (34.7%)0.000
Piperacillin/tazobactam13 (3.8%)33 (13.7%)0.003
Imipenem11 (1.3%)21 (2.1%)0.104
Meropenem12 (2.5%)23 (2.1%)0.085
Tobramycin17 (8.8%)39 (27.4%)0.002

Abbreviations: cKp, classic Klebsiella pneumoniae; ESBLs, extended spectrum β-lactamase; hvKp, hypervirulent Klebsiella pneumoniae.

Risk factors: hvKp vs. cKp

In this study, univariate regression analysis showed that diabetes (odds ratio [OR]=2.903), digestive diseases (OR=2.127), and hypermucoviscosity (OR=17.446) were notable risk factors for hvKp infection. However, indwelling stomach tube (OR=0.447) was a protective factor for hvKp infection. Moreover, multivariate analysis revealed that diabetes (OR=2.566) and hypermucoviscosity (OR=15.249) were independent risk factors for hvKp infections (Table 3).
Table 3

Risk factors for hvKp vs. cKp

VariableUnivariate OR (95% CI)P-valueMultivariate OR (95% CI)P-value
Infection occurred in ICU1.388 (0.668–2.884)0.380
Male1.538 (0.608–3.888)0.363
Hypermucoviscosity17.446 (8.07937.673)0.00015.249 (6.90533.875)0.000
Pulmonary diseases2.125 (0.945–4.779)0.068
Diabetes2.903 (1.6105.236)0.0002.566 (1.2585.235)0.010
Cardiovascular disease0.676 (0.388–1.179)0.168
Cerebrovascular disease0.542 (0.268–1.095)0.088
Cancer1.205 (0.648–2.240)0.556
Surgery within 1 month1.475 (0.635–3.426)0.367
Digestive diseases2.127 (1.0044.505)0.046
Central intravenous catheter1.271 (0.711–2.271)0.419
Urinary catheter0.693 (0.350–1.372)0.293
Tracheal catheter0.942 (0.530–1.673)0.839
Stomach tube0.447 (0.2420.824)0.010

Note: Bold values indicate P<0.05.

Abbreviations: cKp, classic Klebsiella pneumoniae; hvKp, hypervirulent Klebsiella pneumoniae; ICU, intensive care unit; OR, odds ratio.

Risk factors: CR-hvKp vs. non-CR-hvKp

Patients with surgery history within 1 month (OR=19.5) and catheterized tracheal catheter (OR=6.051) were closely associated with CR-hvKp. However, patients with diabetes (OR=0.256) were more likely to be infected with non-CR-hvKp. A history of surgery within the last 1 month is an independent risk factor for CR-hvKp infection (OR=15.999) (Table 4).
Table 4

Risk factor for CR-hvKp vs. non-CR-hvKp

VariableUnivariate OR (95% CI)P-valueMultivariate OR (95% CI)P-value
Hypermucoviscous0.468 (0.086–2.550)0.380
Infection occurred in ICU2.667 (0.692–10.277)0.154
Pulmonary diseases3.879 (0.052–1.112)0.162
Cancer2.246 (0.625–8.077)0.215
Diabetes0.256 (0.0710.930)0.038
Cardiovascular disease0.613 (0.167–2.250)0.461
Cerebrovascular disease3.884 (0.965–15.313)0.056
Surgery within 1 month19.5 (4.56783.265)0.00015.999 (3.41275.026)0.000
Digestive diseases2.386 (0.662–8.602)0.184
Central intravenous catheter2.330 (0.472–11.501)0.299
Tracheal catheter6.051 (1.48524.658)0.012
Stomach tube1.867 (0.462–7.535)0.381
Urinary catheter3.492 (0.422–28.865)0.246

Note: Bold values indicate P<0.05.

Abbreviations: cKp, classic Klebsiella pneumoniae; CR, carbapenems-resistant; hvKp, hypervirulent Klebsiella pneumoniae; ICU, intensive care unit; OR, odds ratio.

MLST genotypic analysis

Among the 202 K. pneumoniae isolates, no new ST was identified in MLST database. The most prevalent ST in this study was ST23 (n=28; 13.9%), followed by ST412 (n=10; 5.0%), ST37 (n=7; 3.5%), ST65 (n=6; 3.0%), ST11 (n=5; 2.5%), ST17 (n=5; 2.5%), ST2905 (n=5; 2.5%), and ST2906 (n=5; 2.5%). The aforementioned STs accounted for 35.1% (43/202) of the total strains. Among the primary STs, ST23 (24/28), ST412 (6/9), ST17(5/5), and ST65(3/6) were strongly associated with hvKp, while ST11(0/5), ST2905(1/5), ST2906(1/5), and ST37(2/7) were more common in the cKp group. The more common clone complexes (CCs) of the CR-hvKp group were CC23 (n=3) and CC17 (n=3). There is an important phenomenon in the phylogenetic tree that a branch clustered with ST347, ST595, ST1469, ST2905, and ST2906 contributed to poor prognosis death in 30 days, which should be paid more attention (Figure 1).
Figure 1

Neighbor-joining dendrogram showing concatenated sequences of 7 housekeeping genes from the MLST database for the frequency >1 STs and isolates contributing to invasive infection and mortality. Yellow solid rim represents death.

Abbreviations: MLST, multilocus sequence typing; ST, sequence type.

Discussion

To our knowledge, this is the first and biggest systematic study focusing on the elderly infected with hvKp in China. In this study, 59.9% of hvKp were identified as hypermucoviscous by string test, which was significantly different from a previous retrospective study conducted in a single center in China, with a prevalence of 33% in Beijing.13 In addition, the incidence of hvKp (47.5%) in genetic background is also higher than the figure in the previous multicenter studies (37.8%).8 It can be concluded that hvKp is emerging as the major pathotype for the elderly in the 2 hospitals, which should be paid more attention. The prevalent ST in 2 hospitals is the same: ST23. However, different hospitals isolated with ST23 are not highly associated with hvKp, which indicates that fully relying on STs to identify hvKp may be unreliable. Although the definition of hvKp is controversial, it is an objective marker, like plasmid type, biofilm producing, serotypes and the ability of trigger inflammatory factors that may be needed for further study to complement the real hypervirulence. Therefore, the prevalence of hvKp may be incorrectly estimated due to the lack of definite and objective diagnostic methods. HvKp causes various severe infections, posing a serious threat to health. Various types of K-antigen have been reported,17,21,22 with the more important elements in Asia being K1 and K2, which are the reason for severe infection. But they are not the unique trait for hvKp.23,24 MagA is not a specific virulence gene for hvKp isolates causing PLA,25 but it is highly associated with cps K1.22,26 Moreover, the mutant isolate (knockout magA) could not show hmv phenotype.27 RmpA/RmpA2 was proposed as a virulent factor in addition to magA and cps K1/K2.16 Although rmpA is not an independent factor contributing to pyogenic liver abscess, it promotes capsule synthesis, which is associated with hypermucoviscous.3,16 Our results are consistent with a previous study: invasive infection (especially liver abscess), hypermucoviscosity, and mainly virulence factors (K1, K2, rmpA, and magA genes) are highly presented in hvKp group.8 So, a better understanding of risk factors is essential to make interventions. Our results show that patients with diabetes are more likely to be infected with hvKp. Additionally, hypermucoviscosity is strongly associated with hvKp. In our study, patients with surgery history of <1 month are an independent risk factor for CR-hvKp infection, which should be focused more on how to prevent infection. A previous study concluded that major histocompatibility complex variants, nutritional status, and gut microbiota are essential host factors to improve the understanding of the hypervirulence phenomenon.7 Our results demonstrated that in the hvKp group, patients with better nutritional status are associated with a more severe SOFA score and more serious inflammation reaction. All aforementioned characteristics may be a potential marker for early and precise empirical interventions for the elderly with hvKp. Previous studies have revealed that most hvKp and antimicrobial-resistant patterns were non-overlapping.8,13 In this study, most hvKp were sensitive to most of the aforementioned antibiotics. In the hvKp group, the number of MDR-hvKp (25.0%) and ESBL-hvKp (26.0%) is significantly higher compared to the previous study performed in the multicenter study, with a prevalence of 12.6%.8 It is alarming that the number of elderly with MDR-hvKp infection is increasing. Moreover, 1 CR-hvKp isolate was detected in 1 hospital, where long-term patients were hospitalized. However, 10 CR-hvKp strains were detected in the other hospital, which was a referral center receiving patients from other hospitals and the community. Therefore, the incidence of CR-hvKp may be underestimated in this region. Thus, these data revealed that MDR-hvKp is emerging among the elderly. However, to confirm this conclusion, further investigation using a larger population is needed. The CR-hvKp was not detected in nosocomial environment by routine nosocomial infection surveillance. In addition, the 2 hospitals did not apply the use of anal swab for monitoring nosocomial infection. It is unclear whether gut microbiota composed of hvKp contributed to the infection. Thus, it is essential to enhance hospital infection surveillance for the elderly. A previous study suggested that wards previously infected with CR-hvKp should be disinfected and left unoccupied for >2 weeks.10 Otherwise it may be a good site for a fatal outbreak of the organism. There are some limitations in our study. First, it was a retrospective study in 2 teaching hospitals for over 10 years. Most key inflammatory and nutrition status marker were not achieved. Second, in vitro and in vivo experiments as objective evidence, such as Galleria mellonella, mouse, or human neutrophil assay, may be needed to identify the real virulent Kp. Third, to further explore the pathogen genomic characteristics, especially for virulent and antibiotic-resistant environment, whole genome sequencing, transcriptomics, and proteomics may be needed. A larger prospective multicenter study, focusing on host, pathogen, and host–pathogen interaction (inflammatory factor), is needed to better defining the hvKp strains.

Conclusion

The prevalence of hvKp may be higher than expected in the elderly. The epidemiology for hvKp in different hospitals is different. Although the definition of hvKp is still controversial, hvKp (aerobactin positive) strains were more likely to cause serious infections, such as liver abscess and septic shock, and more severe inflammatory reaction in the host. To further understand hvKp, host, pathogen, and host–pathogen interaction may be taken into consideration. The emerging MDR-hvKp, especially CR-hvKp, will be a great challenge for treatment. It is essential to enhance clinical awareness and management for the different types of hvKp infections. Primers Detailed clinical and microbiological features of CR-hvKp strains Abbreviations: ALB, albumin; AMK, amikacin; CAZ, ceftazidime; CIP, ciprofloxacin; CMZ, cefmetazole; CVC, central venous catheter; F, female; FOS, fosfomycin; GEN, gentamicin; ICU, intensive care unit; IPM, imipenem; ISE, isepamicin; LEV, levofloxacin; MLST, multilocus sequence typing; M, male; MEM, meropenem; Mo, month; MXF, moxifloxacin; NEU, neutrophils; N, no; PLA; pyogenic liver abscess; SMZ, sulfamethoxazole; SOFA, sequential organ failure assessment; TGC, tigecycline; TOB, tobramycin; TP, total protein; TZP, piperacillin tazobactam; WBC, white blood cell; Y, yes; +, positive; −, negative.
Table S1

Primers

NameSequence
rmpA
 Forward5-ACTGGGCTACCTCTGCTTCA-3
 Reverse5-CTTGCATGAGCCATCTTTCA-3
rmpA2
 Forward5-CTTTATGTGCAATAAG-GATGTT-3
 Reverse5-CCTCCTGGAGAGTAAGCATT-3
magA
 Forward5-GGTGCTCTTTACATCATTGC-3
 Reverse5-GCAATGGCCATTTGCGTTAG-3
aerobactin
 Forward5-GCATAGGCGGATACGAACAT-3
 Reverse5-CACAGGGCAATTGCTTACCT-3
K1
 Forward5-GTAGGTATTGCAAGCCATGC-3
 Reverse5-GCCCAGGTTAATGAATCCGT-3
K2
 Forward5-GGAGCCATTTGAATTCGGTG-3
 Reverse5-TCCCTAGCACTGGCTTAAGT-3
K5
 Forward5-GCCACCTCTAAGCATATAGC-3
 Reverse5-CGCACCAGTAATTCCAACAG-3
K20
 Forward5-CCGATTCGGTCAACTAGCTT-3
 Reverse5-GCACCTCTATGAACTTTCAG-3
K54
 Forward5-CATTAGCTCAGTGGTTGGCT-3
 Reverse5-GCTTGACAAACACCATAGCAG-3
K57
 Forward5-CGACAAATCTCTCCTGACGA-3
 Reverse5-CGCGACAAACATAACACTCG-3
rpoB
 Forward5-GGCGAAATGGCWGAGAACCA-3
 Reverse5-GAGTCTTCGAAGTTGTAACC-3
gapA
 Forward5-TGAAATATGACTCCACTCACGG-3
 Reverse5-CTTCAGAAGCGGCTTTGATGGCTT-3
mdh
 Forward5-TGAAATATGACTCCACTCACGG-3
 Reverse5-CTTCAGAAGCGGCTTTGATGGCTT-3
pgi
 Forward5-GAGAAAAACCTGCCTGTACTGCTGGC-3
 Reverse5-CGCGCCACGCTTTATAGCGGTTAAT-3
phoE
 Forward5-ACCTACCGCAACACCGACTTCTTCGG-3
 Reverse5-TGATCAGAACTGGTAGGTGAT-3
infB
 Forward5-CTCGCTGCTGGACTATATTCG-3
 Reverse5-CGCTTTCAGCTCAAGAACTTC-3
tonB
 Forward5-CTTTATACCTCGGTACATCAGGTT-3
 Reverse5-ATTCGCCGGCTGRGCRGAGAG-3
Table S2

Detailed clinical and microbiological features of CR-hvKp strains

Clinical featuresP1P2P3P4P5P6P7P8P9P10P11
Age (years)8787878879716565778494
GenderFMMFMFFMMMM
Clinical departmentInternal medicineEmergencyGeneral surgeryICUGeneral surgeryICUICUThoracic surgeryICUThoracic surgeryRespiratory
Main underlying diseasesBone fracture; Cardiovascular diseasesDiabetesSurgery with in 1 monthCerebrovascular diseaseCancer; Surgery with in 1 monthCancer; Surgery with in 1 monthDiabetes; Cerebrovascular diseaseCancerCancer; Surgery with in 1 monthSurgery with in 1 monthCancer; Cerebrovascular disease; diabetes
TubeCVC; UreterUreter; Stomach tubeNoneCVC; Ureter; Stomach tube; Tracheal catheterCVC; Ureter; Stomach tube; Tracheal catheterCVC; Ureter; Tracheal catheterCVC; Ureter; Stomach tube; Tracheal catheterCVC; Ureter; Stomach tube; Tracheal catheterCVC; Ureter; Stomach tube; Tracheal catheterCVC; Ureter; Stomach tube; Tracheal catheterCVC; Ureter; Stomach tube; Tracheal catheter
Specimen typeSputumSputumPyogenic fluidsBileSputum +Blood +WoundBile+BloodSputum+Urine +FecesSputumPyogenic fluidsSputum+UrineDrainage liquid
Infection typePneumoniaPneumoniaAbscessPLASepsisSeptic shockSeptic shockSepsisSeptic shockSeptic shockSepsis
WBC(109/L)12.2110.8513.7616.448.8015.4910.018.3211.669.514.64
NEU (%)75.186.692.582.256.883.469.987.488.065.268.3
TP (g/L)79.460.569.452.854.749.65970.96267.461.2
ALB (g/L)40.327.734.628.220.630.032.636.427.431.735.0
Sensitive antibioticsNNNNGEN; LEV; TOBNSMZ; TOB; AMKSMZNNSMZ; AMK
SOFA score6102137974567
Empiric therapyCIP+CAZCIP+CAZIPMIPM+ISEIPM+MXFCIP+CAZIPM+ISEIPMIPMMXFMEM
Switched therapyMEM+TGCMEM+TGCTGCTGCGEN+LEVTGC+MEMTGC+MEM+FOSTGC+MEMTGC+MEMTGC+MEM+FOSTGC
Clinical outcomeSurvivedSurvivedSurvivedSurvivedSurvivedSurvivedSurvivedDiedSurvivedSurvivedSurvived
String test+++++++++
Virulence-associated genes
rmpA+++++++++
rmpA2+++++++++
magA++++++++++
cps genes
K1++++++
K2++++++++
K5++
K20+++
K54+
K57++
MLST genotyping232317173471729052906234122874

Abbreviations: ALB, albumin; AMK, amikacin; CAZ, ceftazidime; CIP, ciprofloxacin; CMZ, cefmetazole; CVC, central venous catheter; F, female; FOS, fosfomycin; GEN, gentamicin; ICU, intensive care unit; IPM, imipenem; ISE, isepamicin; LEV, levofloxacin; MLST, multilocus sequence typing; M, male; MEM, meropenem; Mo, month; MXF, moxifloxacin; NEU, neutrophils; N, no; PLA; pyogenic liver abscess; SMZ, sulfamethoxazole; SOFA, sequential organ failure assessment; TGC, tigecycline; TOB, tobramycin; TP, total protein; TZP, piperacillin tazobactam; WBC, white blood cell; Y, yes; +, positive; −, negative.

  27 in total

Review 1.  Hypervirulence and hypermucoviscosity: Two different but complementary Klebsiella spp. phenotypes?

Authors:  Juan Carlos Catalán-Nájera; Ulises Garza-Ramos; Humberto Barrios-Camacho
Journal:  Virulence       Date:  2017-04-12       Impact factor: 5.882

2.  The distant metastasis of pyogenic liver abscess caused by Klebsiella pneumoniae serotype K2 and the underlying disease of diabetes mellitus should be carefully interpreted.

Authors:  Jung-Chung Lin; Kuo-Ming Yeh; Feng-Yee Chang
Journal:  Clin Infect Dis       Date:  2007-12-01       Impact factor: 9.079

3.  Clinical and phenotypic differences between classic and hypervirulent Klebsiella pneumonia: an emerging and under-recognized pathogenic variant.

Authors:  D K Pomakova; C-B Hsiao; J M Beanan; R Olson; U MacDonald; Y Keynan; T A Russo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-09-15       Impact factor: 3.267

4.  High Prevalence of Hypervirulent Klebsiella pneumoniae Infection in China: Geographic Distribution, Clinical Characteristics, and Antimicrobial Resistance.

Authors:  Yawei Zhang; Chunjiang Zhao; Qi Wang; Xiaojuan Wang; Hongbin Chen; Henan Li; Feifei Zhang; Shuguang Li; Ruobing Wang; Hui Wang
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

5.  Investigation of the putative virulence gene magA in a worldwide collection of 495 Klebsiella isolates: magA is restricted to the gene cluster of Klebsiella pneumoniae capsule serotype K1.

Authors:  Carsten Struve; Martin Bojer; Eva Møller Nielsen; Dennis Schrøder Hansen; Karen A Krogfelt
Journal:  J Med Microbiol       Date:  2005-11       Impact factor: 2.472

6.  Aerobactin, but not yersiniabactin, salmochelin, or enterobactin, enables the growth/survival of hypervirulent (hypermucoviscous) Klebsiella pneumoniae ex vivo and in vivo.

Authors:  Thomas A Russo; Ruth Olson; Ulrike MacDonald; Janet Beanan; Bruce A Davidson
Journal:  Infect Immun       Date:  2015-06-08       Impact factor: 3.441

7.  Capsular serotype K1 or K2, rather than magA and rmpA, is a major virulence determinant for Klebsiella pneumoniae liver abscess in Singapore and Taiwan.

Authors:  Kuo-Ming Yeh; A Kurup; L K Siu; Y L Koh; Chang-Phone Fung; Jung-Chung Lin; Te-Li Chen; Feng-Yee Chang; Tse-Hsien Koh
Journal:  J Clin Microbiol       Date:  2006-12-06       Impact factor: 5.948

8.  Loss of hypermucoviscosity and increased fitness cost in colistin-resistant Klebsiella pneumoniae sequence type 23 strains.

Authors:  Myung-Jin Choi; Kwan Soo Ko
Journal:  Antimicrob Agents Chemother       Date:  2015-08-17       Impact factor: 5.191

9.  Virulent clones of Klebsiella pneumoniae: identification and evolutionary scenario based on genomic and phenotypic characterization.

Authors:  Sylvain Brisse; Cindy Fevre; Virginie Passet; Sylvie Issenhuth-Jeanjean; Régis Tournebize; Laure Diancourt; Patrick Grimont
Journal:  PLoS One       Date:  2009-03-25       Impact factor: 3.240

10.  Microbiological and clinical characteristics of bacteraemia caused by the hypermucoviscosity phenotype of Klebsiella pneumoniae in Korea.

Authors:  S W Jung; H J Chae; Y J Park; J K Yu; S Y Kim; H K Lee; J H Lee; J M Kahng; S O Lee; M K Lee; J H Lim; C H Lee; S J Chang; J Y Ahn; J W Lee; Y G Park
Journal:  Epidemiol Infect       Date:  2012-05-14       Impact factor: 4.434

View more
  19 in total

1.  Clinical and Microbiological Prognostic Factors of in-Hospital Mortality Caused by Hypervirulent Klebsiella pneumoniae Infections: A Retrospective Study in a Tertiary Hospital in Southwestern China.

Authors:  Yu Tang; Hang Liu; Jinxin Zhao; Miao Yi; Yaling Yuan; Yun Xia
Journal:  Infect Drug Resist       Date:  2020-10-21       Impact factor: 4.003

2.  Molecular characterization of extended-spectrum β-lactamase-producing Klebsiella pneumoniae from a Malaysian hospital.

Authors:  Golnaz Mobasseri; Kwai Lin Thong; Ganeswarie Rajasekaram; Cindy Shuan Ju Teh
Journal:  Braz J Microbiol       Date:  2019-12-14       Impact factor: 2.476

Review 3.  Hypervirulent Klebsiella pneumoniae - clinical and molecular perspectives.

Authors:  J E Choby; J Howard-Anderson; D S Weiss
Journal:  J Intern Med       Date:  2019-11-21       Impact factor: 8.989

4.  Diversity and frequency of resistance and virulence genes in bla KPC and bla NDM co-producing Klebsiella pneumoniae strains from China.

Authors:  Xin Liu; Jie Zhang; Yini Li; Qiuni Shen; Wenting Jiang; Kelei Zhao; Yancheng He; Penggao Dai; Zhihao Nie; Xiyan Xu; Yingshun Zhou
Journal:  Infect Drug Resist       Date:  2019-09-10       Impact factor: 4.003

5.  Phenotypic and Genomic Characterization of Virulence Heterogeneity in Multidrug-Resistant ST11 Klebsiella pneumoniae During Inter-Host Transmission and Evolution.

Authors:  Chao Liu; Pengcheng Du; Jiankang Zhao; Binbin Li; Chunlei Wang; Lingxiao Sun; Binghuai Lu; Yimin Wang; Yingmei Liu; Bin Cao
Journal:  Infect Drug Resist       Date:  2020-06-10       Impact factor: 4.003

6.  A 7-year surveillance of the drug resistance in Klebsiella pneumoniae from a primary health care center.

Authors:  Guogang Li; Sheng Zhao; Sipei Wang; Yingqian Sun; Yangxiao Zhou; Xinling Pan
Journal:  Ann Clin Microbiol Antimicrob       Date:  2019-11-09       Impact factor: 3.944

7.  Prevalence and characteristics of surgical site hypervirulent Klebsiella pneumoniae isolates.

Authors:  Qiang Zhao; Ling Guo; Li-Feng Wang; Qian Zhao; Ding-Xia Shen
Journal:  J Clin Lab Anal       Date:  2020-05-19       Impact factor: 2.352

8.  Clinical and Molecular Characteristics of Carbapenem-Resistant Hypervirulent Klebsiella pneumoniae Isolates in a Tertiary Hospital in Shanghai, China.

Authors:  Cong Zhou; Qiang Wu; Leqi He; Hui Zhang; Maosuo Xu; Baoyu Yuan; Zhi Jin; Fang Shen
Journal:  Infect Drug Resist       Date:  2021-07-14       Impact factor: 4.003

9.  Clinical and computed tomography features of extended-spectrum β-lactamase-producing Klebsiella pneumoniae liver abscess.

Authors:  Yue Ren; Hairui Wang; Zhihui Chang; Zhaoyu Liu
Journal:  BMC Infect Dis       Date:  2020-06-15       Impact factor: 3.090

10.  Hypervirulent Klebsiella pneumoniae is emerging as an increasingly prevalent K. pneumoniae pathotype responsible for nosocomial and healthcare-associated infections in Beijing, China.

Authors:  Chao Liu; Pengcheng Du; Nan Xiao; Fansen Ji; Thomas A Russo; Jun Guo
Journal:  Virulence       Date:  2020-12       Impact factor: 5.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.